Mwyngil Therapeutics Launches Phase 1 Study for Neuroinflammatory Treatment Candidate BT-409 Mwyngil Therapeutics announces a Phase 1 study for BT-409, a promising NLRP3 inhibitor targeting neuroinflammatory conditions like MS and PD.

Mwyngil Therapeutics Launches Phase 1 Study for Neuroinflammatory Treatment Candidate BT-409 #United_States #Dover,_Delaware #Mwyngil_Therapeutics #BT-409 #NLRP3_Inhibitor

Insilico Medicine's ISM8969 Achieves IND Approval from FDA, Pioneering AI-Led Drug Development Insilico Medicine's ISM8969 secures IND approval from the FDA, paving the way for clinical trials, showcasing AI's potential in drug development.

Insilico Medicine's ISM8969 Achieves IND Approval from FDA, Pioneering AI-Led Drug Development #United_States #Cambridge #Insilico_Medicine #NLRP3_Inhibitor #ISM8969

Insilico Medicine and Hygtia Therapeutics Team Up on Groundbreaking NLRP3 Inhibitor for CNS Diseases Insilico Medicine and Hygtia Therapeutics have announced a strategic collaboration to co-develop ISM8969, an innovative NLRP3 inhibitor targeting CNS disorders, highlighting a significant advancement in therapeutic options.

Insilico Medicine and Hygtia Therapeutics Team Up on Groundbreaking NLRP3 Inhibitor for CNS Diseases #None #Insilico_Medicine #Hygtia_Therapeutics #NLRP3_Inhibitor